Skip to main content

Paroxysmal Supraventricular Tachycardia

8
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
6
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Milestone Pharmaceuticals
CARDAMYSTApproved
etripamil
Milestone Pharmaceuticals
nasal2025

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Milestone Pharmaceuticals
5 programs
1
4
1
EtripamilPhase 3
Etripamil NSPhase 3
Etripamil NS 70 mgPhase 31 trial
Etripamil NS 70 mgPhase 3
Etripamil NSPhase 21 trial
Active Trials
NCT05763953Recruiting60Est. Jun 2027
NCT04952610Enrolling By Invitation130Est. Mar 2026
Medpace
MedpaceCINCINNATI, OH
2 programs
2
EtripamilPhase 3
Etripamil NS 70 mgPhase 31 trial
Active Trials
NCT03635996Terminated169Est. Nov 2020
IQVIA
IQVIADURHAM, NC
2 programs
EtripamilPHASE_31 trial
Etripamil NSPHASE_31 trial
Active Trials
NCT03464019Terminated1,097Est. Jan 2023
NCT04072835Completed1,116Est. Jan 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Milestone PharmaceuticalsEtripamil NS 70 mg
IQVIAEtripamil NS
MedpaceEtripamil NS 70 mg
IQVIAEtripamil
Milestone PharmaceuticalsEtripamil NS

Clinical Trials (5)

Total enrollment: 2,572 patients across 5 trials

NCT04952610Milestone PharmaceuticalsEtripamil NS 70 mg

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Start: Dec 2021Est. completion: Mar 2026130 patients
Phase 3Enrolling By Invitation
NCT04072835IQVIAEtripamil NS

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

Start: Sep 2019Est. completion: Jan 20231,116 patients
Phase 3Completed
NCT03635996MedpaceEtripamil NS 70 mg

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Start: Dec 2018Est. completion: Nov 2020169 patients
Phase 3Terminated
NCT03464019IQVIAEtripamil

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Start: Jun 2018Est. completion: Jan 20231,097 patients
Phase 3Terminated
NCT05763953Milestone PharmaceuticalsEtripamil NS

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

Start: Dec 2023Est. completion: Jun 202760 patients
Phase 2Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,572 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.